Collaborators
Dr David Fox
Since leaving the Graingerlab to form his own chemistry group at the University of Warwick, David Fox has continued to collaborate extensively with the Graingerlab, both on our BSCI programme, where he is now independently funded by Funxional Therapeutics to expand on the array of BSCI molecules he has synthesized, and on our newer DPPI inhibitor programme. Current areas of collaboration include new solid phase approaches to make naturally occuring caprolactam containing peptides.
http://www2.warwick.ac.uk/fac/sci/chemistry/research /syntheticchemistry/fox/foxgroup
Dr. Christopher Martyn
We have collaborated with Dr Martyn and his colleagues on a number of epidemiology projects over the last couple of years. Most of these projects relate to the way in which environmental factors, particularly those early in life, might influence the circulating levels of chemokines, and hence the function of the adult immune system. More recently, we have extended our collaboration to the application of metabonomic analysis of the Sheffield cohort.
Professor Jeremy Nicholson
Prof. Nicholson, together with his colleagues Dr Elaine Holmes and Prof John Lindon, is one of the world's leading scientists in the field of metabolic profiling. Our collaboration with his laboratory has brought real progress in the field of clinical metabonomics, and continues to yield fascinating data.
Prof. Tim Spector
We have collaborated with Prof. Spector and his colleagues to study the contribution of genetics to circulating levels of cytokines. The Twin Research Unit holds one of the most valuable repositories of samples from twins in the world, which can be analysed extensively, using classical twin study methodology, to reveal both genetic and environmental influences on a range of parameters. Most recently, we have begun to examine the role of genetics in regulating the metabolic signature, revealed by metabonomic analysis.
Prof. Doug Kell
We have collaborated with Prof. Kell and his colleagues at Manchester University to apply GC-MS metabolic profiling to a range of neurodegenerative diseases, including Huntington's Disease and Parkinson's Disease. Through this collaboration we have also begun to compare the use of genetic algorithms with the project-based methods of pattern recognition.